Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Seres Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.100 a question during this time, simply press star followed by the number one on your 00:00:05.100 -- 00:00:10.711 telephone keypad. If you would like to withdraw your question, press star one again. 00:00:10.711 -- 00:00:13.997 Thank you. I would now like to turn the call over to Dr. 00:00:13.997 -- 00:00:19.487 Carlo Tanzi of Investor Relations. Please go ahead. 00:00:19.487 -- 00:00:23.897 Thank you and good morning. Today, before market opens, We issued a press release with 00:00:23.897 -- 00:00:29.243 our third quarter 2025 financial results and business updates available on the investors 00:00:29.243 -- 00:00:34.629 and news section of our website. We've also posted an updated corporate presentation. 00:00:34.629 -- 00:00:38.734 Before we begin, I'd like to remind everyone that we're making forelooking statements, 00:00:38.734 -- 00:00:43.880 including statements around the results of our current or planned clinical trials, 00:00:43.880 -- 00:00:49.287 studies, and data readouts, our product candidates and their potential benefits, development 00:00:49.287 -- 00:00:54.725 plans, and potential commercial opportunities, interactions with and feedback 00:00:54.725 -- 00:00:59.811 from the FDA, our ability to secure an R&D or other partnership and or 00:00:59.811 -- 00:01:04.917 generate or obtain additional capital, financing, or other resources, 00:01:04.917 -- 00:01:10.524 our plan's strategic focus and operating plans, cost reduction actions and anticipated 00:01:10.524 -- 00:01:15.890 benefits and cash runway, the timing of and the foregoing, and other statements 00:01:15.890 -- 00:01:21.197 which are not historical facts. Actual results may differ materially due to various 00:01:21.197 -- 00:01:26.218 risks and uncertainties, a...